Intellia Therapeutics is trading 5.8% up at $11.89 after investors weighed August 6 earnings against encouraging lonvo-z progress.
- EPS of $0.80 matched estimates, while collaboration revenue fell to $7.7 million from $14.2 million, missing expectations.
- Positive Phase 3 HAELO results, an on-track rolling BLA submission and a potential early-2027 launch strengthened the commercial outlook.
- Broader biotech and growth-stock strength also supports the move.